Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGH-BPH1 in Benign Prostatic Hyperplasia
NCT03829904Phase 2Completed
- Sponsor
- Taipei Veterans General Hospital
- Start
- Mar 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VGH-BPH1 in benign prostatic hyperplasia (BPH), sponsored by Taipei Veterans General Hospital. Primary endpoint: International Prostate Symptom Score at 18 weeks. Started Mar 2019; status: completed.
02
Drugs
VGH-BPH1
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT03829904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829904.